NSI-189 is an oral investigational compound that promotes hippocampal neurogenesis and is used off‑label for depression and mood improvement based on community reports, as well as for cognitive enhancement and focus. Most users report taking around 40 mg per day (with a reported range of 200 µg to 50 mg), without a consistent schedule or cycling pattern. The evidence base is thin — most exploratory indications lack posted results and there is no FDA‑approved use, while sleep and dream changes are occasionally reported by a minority of users.
Data last updated
Measured on 5 of 6 axes
Evidence shape
NSI-189 carries low evidence, resting on a single published human study in treatment studies (including depression). Among four registered trials, two have completed, the highest tier reaches only Phase 1, and just one linked publication exists, with no blinded, results‑posted studies beyond that initial human trial. The mapped indications split into three thin/exploratory areas, one animal‑only preclinical topic, and a single‑trial long‑tail, leaving most indications without larger trials or posted results.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Depression
2 studies · 2 completed
Major Depressive Disorder
2 studies
Treatment studies
1 study
2 completed study rows are present, but endpoint pass/fail classification is still pending.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column
How NSI-189 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
The two completed trials of NSI‑189 did not provide a reliably extracted dose; participants received the peptide orally each day, but the exact milligram amount per administration is not reported.
No structured protocol details captured for this tier yet.
Community reports center around 40 mg taken orally, with most sources falling in the 20–80 mg range; a smaller subset reports doses of 200–600 mcg. Dosing frequency was not consistently specified across these reports.